The Carcinogenic Potency Project

Benzene (CAS 71-43-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ezy nas orc ski sto vsc ezy nas orc sto vsc ezy hag hmo lun pre ezy hmo lun mgl ova 169m 77.5m,v

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   ezy = ear/Zymbal’s gland. hag = harderian gland. hmo = hematopoietic system. lun = lung. mgl = mammary gland. nas = nasal cavity (includes tissues of the nose, nasal turbinates, paranasal sinuses and trachea). orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). ova = ovary. pre = preputial gland. ski = skin. sto = stomach. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Benzene: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



BENZENE   71-43-2
615  M f b6c gav 24m24 TR289 :                       0    17.7mg  35.4mg  70.7mg
 MXB MXB        23.7mg * P<.0005    14.9mg 50.7mg  17/50   28/50   41/50   42/50    lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp,
                                                              mlu,mno; ova:gct,lut,mtb,pcy,tua; spl:mlm,mlu,mno; ute:mlh; zym:sqc. M
 MXB MXB        24.6mg * P<.0005    15.3mg 54.6mg  17/50   28/50   40/50   41/50    lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp,
                                                                          mlu,mno; ova:gct,mtb; spl:mlm,mlu,mno; ute:mlh; zym:sqc. C
 liv hpa        38.1mg Z P<.008     15.9mg 880.mg   1/50    8/50   (5/50    4/50)                                                  S
 liv MXA        53.6mg Z P<.009     26.3mg 2.27gm   4/50   12/50   13/50   (7/50)                                     liv:hpa,hpc. S
 ova mtb        66.5mg Z P<.0005 c  34.6mg 156.mg   0/50    1/50   12/50   (7/50)
 lun MXA        83.6mg * P<.002  c  44.0mg 354.mg   4/50    5/50   10/50   13/50                                      lun:a/a,a/c.
 lun a/c        117.mg * P<.0005 c  63.4mg 390.mg   0/50    3/50    6/50    6/50
 ova MXB        119.mg * P<.0005    63.8mg 374.mg   0/50    2/50    7/50    5/50                                  ova:lut,pcy,tua. P
 mgl MXA        132.mg * P<.0005 c  73.1mg 294.mg   0/50    2/50    5/50   10/50                                      mgl:can,sqc.
 ova MXA        146.mg * P<.002     74.0mg 571.mg   1/50    1/50    6/50    8/50                                      ova:gcc,gct. S
 ova gct        157.mg * P<.002  c  77.1mg 793.mg   1/50    1/50    6/50    7/50
 ova tua h      295.mg * P<.006  p  120.mg 3.25gm   0/50    0/50    3/50    3/50
 mgl cas        382.mg * P<.005  c  143.mg 3.12gm   0/50    0/50    1/50    4/50
 hag can        509.mg * P<.006     174.mg 5.94gm   0/50    0/50    0/50    4/50                                                   S
 MXA MXA        79.1mg * P<.04      34.3mg n.s.s.  15/50   25/50   26/50   22/50     mul:lkn,mlh,mlm,mlp,mlu,mno,ule; spl:mlm,mlu,
                                                                                                                     mno; ute:mlh. S
 MXA MXA        94.2mg * P<.07   c  37.2mg n.s.s.  15/50   24/50   24/50   20/50    mul:mlh,mlm,mlp,mlu,mno; spl:mlm,mlu,mno; ute:
                                                                                                                              mlh.
 hag MXA        128.mg * P<.02      57.4mg n.s.s.   5/50    6/50   10/50   10/50                                      hag:adn,can. S
 lun a/a        169.mg * P<.02   c  72.8mg n.s.s.   4/50    2/50    5/50    9/50
 MXA sqp        173.mg * P<.02      77.4mg n.s.s.   1/50    3/50    6/50    5/50                                 cst:sqp; sto:sqp. S
 ova lut h      245.mg * P<.05   p  106.mg n.s.s.   0/50    2/50    3/50    2/50
 zym sqc        421.mg * P<.02   c  146.mg n.s.s.   0/50    0/50    1/50    3/50
 ova pcy h      574.mg * P<.08   p  174.mg n.s.s.   0/50    0/50    2/50    1/50
 TBA MXB        30.4mg * P<.002     16.1mg 158.mg  36/50   40/50   48/50   48/50
 liv MXB        53.6mg Z P<.009     26.3mg 2.27gm   4/50   12/50   13/50   (7/50)                                 liv:hpa,hpc,nnd.
 lun MXB        83.6mg * P<.002     44.0mg 354.mg   4/50    5/50   10/50   13/50                                      lun:a/a,a/c.
616  M m b6c gav 24m24 TR289 :                       0    17.7mg  35.4mg  71.4mg
 MXB MXB        15.1mg * P<.0005    10.1mg 26.0mg  13/50   28/50   35/50   42/50    hag:adn; lun:a/a,a/c; mul:mlh,mlm,mlp,mlu,mno;
                                                                                                    pre:sqc; spl:mlh,mno; zym:sqc. C
 pre MXA        21.8mg Z P<.0005    15.1mg 32.6mg   0/50    5/50   19/50   31/50                                      pre:can,sqc. S
 pre sqc        25.5mg Z P<.0005 c  17.3mg 38.9mg   0/50    3/50   18/50   28/50
 hag MXA        39.5mg * P<.0005    24.5mg 79.0mg   1/50   10/50   13/50   14/50                                      hag:adn,can. S
 hag adn        40.7mg * P<.0005 c  25.7mg 73.0mg   0/50    9/50   13/50   11/50
 lun MXA        42.5mg * P<.0005 c  24.1mg 121.mg  10/50   16/50   19/50   21/50                                      lun:a/a,a/c.
 MXA MXA        50.9mg * P<.0005    28.4mg 141.mg   4/50   10/50   10/50   15/50         mul:lkn,mlh,mlm,mlp,mlu,mno; spl:mlh,mno. S
 MXA MXA        51.8mg * P<.0005 c  28.8mg 141.mg   4/50    9/50    9/50   15/50             mul:mlh,mlm,mlp,mlu,mno; spl:mlh,mno.
 zym sqc        56.3mg Z P<.0005 c  33.8mg 101.mg   0/50    1/50    4/50   21/50
 lun a/c        59.5mg * P<.0005 c  31.8mg 214.mg   5/50   11/50   12/50   14/50
 lun a/a        103.mg * P<.004     48.7mg 900.mg   6/50    6/50    8/50   12/50                                                   S
 adr phe        116.mg Z P<.01      47.9mg 14.1gm   1/50    1/50    7/50   (1/50)                                                  S
 ski MXA        262.mg * P<.004     94.4mg 1.96gm   0/50    0/50    2/50    3/50                                      ski:sqc,squ. S
 MXA mlh        269.mg * P<.005  c  98.0mg 2.24gm   0/50    0/50    3/50    3/50                                 mul:mlh; spl:mlh.
 MXA MXA        169.mg * P<.02      66.5mg n.s.s.   2/50    2/50    3/50    5/50                             cst:sqc,sqp; sto:sqc. S
 cst sqp        222.mg * P<.03      80.3mg n.s.s.   2/50    1/50    2/50    5/50                                                   S
 TBA MXB        17.1mg * P<.0005    10.4mg 38.6mg  33/50   40/50   48/50   46/50
 liv MXB        102.mg * P<.2       35.1mg n.s.s.  15/50   17/50   22/50   11/50                                  liv:hpa,hpc,nnd.
 lun MXB        42.5mg * P<.0005    24.1mg 121.mg  10/50   16/50   19/50   21/50                                      lun:a/a,a/c.
617  M m aks inh 72w72 1048                          0    83.7mg                                         Snyder;txap,54,323-331;1980
 --- mly e      114.mg   P<.3    -  32.4mg n.s.s.  24/50   29/49
618  M m c56 inh 69w69 1048                          0    251.mg
 thm lym h      466.mg   P<.004  +  190.mg 2.81gm   0/40    6/40
 --- mix h      441.mg   P<.04   +  167.mg n.s.s.   2/40    8/40
 --- lcl h      681.mg   P<.2    +  212.mg n.s.s.   2/40    6/40
619  M f swi gav 18m24 BT908                         0    241.mg                                       Maltoni;anya,534,412-426;1988
 mam car        279.mg   P<.0005 +  154.mg 655.mg   2/40   19/40
 lun mix        453.mg   P<.004  +  214.mg 3.43gm   4/40   15/40
 lun ata        1.02gm   P<.004     414.mg 6.13gm   0/40    6/40
 lun ade        1.10gm   P<.2       362.mg n.s.s.   4/40    9/40
 zym car        6.52gm   P<.3    +  1.06gm n.s.s.   0/40    1/40
 liv hpt        no dre   P=1.       1.99gm n.s.s.   0/40    0/40
 tba mix        150.mg   P<.0005    77.1mg 523.mg  16/40   32/40
 tba mal        187.mg   P<.0005 +  99.1mg 589.mg  11/40   28/40
620  M m swi gav 18m24 BT908                         0    241.mg
 lun mix        382.mg   P<.0005 +  193.mg 1.39gm   3/40   16/40
 lun ade        811.mg   P<.02      330.mg n.s.s.   2/40    9/40
 lun ata        1.20gm   P<.04      436.mg n.s.s.   1/40    6/40
 zym car        1.57gm   P<.02   +  541.mg n.s.s.   0/40    4/40
 liv hpt        6.19gm   P<.7       756.mg n.s.s.   2/40    3/40
 lun adc        6.52gm   P<.3       1.06gm n.s.s.   0/40    1/40
 tba mix        370.mg   P<.05      149.mg n.s.s.  15/40   24/40
 tba mal        939.mg   P<.3    +  279.mg n.s.s.   9/40   14/40
621  R f f34 gav 24m24 TR289 :                       0    17.7mg  35.4mg  70.7mg
 MXB MXB        55.1mg * P<.0005    37.2mg 96.2mg   1/50   10/50   16/50   21/50  cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp; zym:
                                                                                                                              can. C
 zym MXA        97.9mg * P<.0005    60.8mg 179.mg   0/50    5/50    6/50   15/50                                      zym:adn,can. S
 zym can        109.mg * P<.0005 c  66.3mg 207.mg   0/50    5/50    5/50   14/50
 MXA MXA        113.mg * P<.0005 c  65.7mg 333.mg   1/50    5/50   12/50    9/50       cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp.
 ute esp        158.mg * P<.008     73.3mg 4.18gm   7/50    7/50    7/50   14/50                                                   S
 MXA sqp        186.mg * P<.01   c  90.9mg 13.1gm   1/50    4/50    8/50    5/50               cst:sqp; lpp:sqp; pal:sqp; ton:sqp.
 MXA sqc        290.mg * P<.002  c  141.mg 1.14gm   0/50    1/50    4/50    5/50                                 pal:sqc; ton:sqc.
 ton MXA        295.mg * P<.003  c  143.mg 1.56gm   0/50    1/50    5/50    4/50                                      ton:sqc,sqp.
 ton sqc        368.mg * P<.003  c  166.mg 1.76gm   0/50    0/50    4/50    4/50
 pal MXA        288.mg * P<.06   c  118.mg n.s.s.   1/50    4/50    5/50    4/50                                      pal:sqc,sqp.
 MXA MXA        364.mg * P<.04      157.mg n.s.s.   0/50    2/50    3/50    2/50                             cvu:adq; utm:acn,can. S
 TBA MXB        46.7mg * P<.006     23.3mg 567.mg  38/50   39/50   41/50   42/50
 liv MXB        no dre   P=1.       238.mg n.s.s.   0/50    3/50    1/50    0/50                                  liv:hpa,hpc,nnd.
622  R m f34 gav 24m24 TR289 :                       0    35.4mg  70.7mg  142.mg
 MXB MXB        51.1mg * P<.0005    35.9mg 83.8mg   3/50   21/50   27/50   37/50   lpp:sqc,sqp; pal:sqc,sqp; ski:sqc,sqp; ton:sqc,
                                                                                                                     sqp; zym:can. C
 MXA MXA        91.5mg * P<.0005 c  59.4mg 174.mg   1/50    9/50   16/50   19/50            lpp:sqc,sqp; pal:sqc,sqp; ton:sqc,sqp.
 MXA sqp        140.mg * P<.0005 c  84.2mg 334.mg   1/50    6/50   11/50   13/50                        lpp:sqp; pal:sqp; ton:sqp.
 zym MXA        155.mg * P<.0005    92.8mg 363.mg   2/50    7/50   10/50   18/50                                      zym:adn,can. S
 zym can        166.mg * P<.0005 c  98.3mg 401.mg   2/50    6/50   10/50   17/50
 ski MXA        181.mg * P<.0005    102.mg 544.mg   1/50    7/50    5/50   12/50                              ski:adq,sqc,sqp,ulc. S
 ski MXA        191.mg * P<.0005    105.mg 656.mg   1/50    7/50    5/50   11/50                                  ski:adq,sqc,sqp. S
 lpp MXA        220.mg * P<.0005 c  120.mg 519.mg   0/50    2/50    5/50    8/50                                      lpp:sqc,sqp.
 pal MXA        243.mg * P<.0005 c  135.mg 635.mg   0/50    4/50    5/50    9/50                                      pal:sqc,sqp.
 pal sqp        250.mg * P<.0005 c  138.mg 668.mg   0/50    4/50    4/50    9/50
 ski sqc        260.mg * P<.0005 c  143.mg 859.mg   0/50    5/50    3/50    8/50
 lpp sqp        284.mg * P<.002  c  145.mg 986.mg   0/50    2/50    5/50    5/50
 MXA sqc        295.mg * P<.0005 c  156.mg 977.mg   0/50    3/50    5/50    7/50                        lpp:sqc; pal:sqc; ton:sqc.
 ski sqp        427.mg * P<.003  c  192.mg 2.56gm   0/50    2/50    1/50    5/50
 ton MXA        382.mg * P<.02   c  173.mg n.s.s.   1/50    3/50    6/50    6/50                                      ton:sqc,sqp.
 ton sqc        430.mg * P<.02   c  206.mg n.s.s.   0/50    3/50    4/50    4/50
 lpp sqc        1.15gm * P<.02   c  349.mg n.s.s.   0/50    0/50    0/50    3/50
 TBA MXB        68.1mg * P<.006     33.7mg 799.mg  39/50   44/50   45/50   47/50
 liv MXB        1.91gm * P<.7       261.mg n.s.s.   2/50    2/50    5/50    1/50                                  liv:hpa,hpc,nnd.
623  R f sda inh 24m35 BT4004                        0    53.4mg                                         Maltoni;ajim,7,415-446;1985
 mgl mal egv    907.mg   P<.1       291.mg n.s.s.   2/60    6/54
 orc car egv    2.02gm   P<.09      496.mg n.s.s.   0/60    2/54
 zym car egv    1.89gm   P<.3       433.mg n.s.s.   1/60    3/54
 liv hpt egv    4.07gm   P<.3       663.mg n.s.s.   0/60    1/54
 nas car egv    4.07gm   P<.3       663.mg n.s.s.   0/60    1/54
 tba car egv    947.mg   P<.07      314.mg n.s.s.   1/60    5/54
 tba mal egv    553.mg   P<.2    +  181.mg n.s.s.   9/60   14/54
624  R f sda gav 12m33 BT901                         0    11.6mg  58.0mg                            Maltoni;ajim,7,415-446;1985/1979
 zym car ej     222.mg * P<.0005 +  108.mg 716.mg   0/30    2/28    8/28
 orc car ej     945.mg * P<.04   +  232.mg n.s.s.   0/29    0/24    2/21
 mgl mal ej     517.mg * P<.3       141.mg n.s.s.   4/30    4/28    7/28
 liv hpt ej     no dre   P=1.       74.1mg n.s.s.   0/13    0/30    0/7
 ski car ej     no dre   P=1.       117.mg n.s.s.   0/30    0/30    0/35
 --- leu ej     no dre   P=1.       382.mg n.s.s.   1/30    2/30    1/29
 tba mal ej     75.3mg * P<.0005    39.4mg 237.mg   7/30   10/28   21/29
625  R f sda gav 24m33 BT902                         0    237.mg                                         Maltoni;ajim,7,415-446;1985
 orc car e      415.mg   P<.0005 +  242.mg 794.mg   0/49   20/39
 zym car e      585.mg   P<.0005 +  324.mg 1.21gm   0/49   16/40
 for cic e      787.mg   P<.002  +  318.mg 3.25gm   0/24    6/19
 liv hpt e      4.03gm   P<.3       655.mg n.s.s.   0/15    1/14
 liv ang e      7.91gm   P<.2    +  1.29gm n.s.s.   0/35    1/27
 nas car e      8.51gm   P<.2    +  1.39gm n.s.s.   0/40    1/29
 ski car e      no dre   P=1.       2.42gm n.s.s.   1/35    0/27
 tba mal e      161.mg   P<.0005    92.3mg 312.mg  10/49   35/40
 tba car        248.mg   P<.0005    152.mg 432.mg   0/50   28/40
626  R m sda gav 12m33 BT901                         0    11.6mg  58.0mg                            Maltoni;ajim,7,415-446;1985/1979
 --- leu ej     506.mg * P<.008     175.mg 8.25gm   0/22    0/23    4/24
 liv hpt ej     3.09gm * P<.2       503.mg n.s.s.   0/30    0/30    1/35
 sub ang ej     3.09gm * P<.2       503.mg n.s.s.   0/30    0/30    1/35
 mgl mal ej     no dre   P=1.       84.1mg n.s.s.   0/22    0/22    0/22
 orc car ej     no dre   P=1.       74.2mg n.s.s.   0/19    0/20    0/17
 ski car ej     no dre   P=1.       117.mg n.s.s.   0/30    0/30    0/35
 zym car ej     no dre   P=1.       84.1mg n.s.s.   0/22    0/22    0/22
 tba mal ej     232.mg * P<.004     101.mg 1.63gm   1/22    1/23    8/24
627  R m sda gav 24m33 BT902                         0    237.mg                                         Maltoni;ajim,7,415-446;1985
 orc car e      386.mg   P<.0005 +  227.mg 727.mg   0/45   21/39
 zym car e      501.mg   P<.0005 +  280.mg 1.07gm   1/45   18/39
 ski car e      904.mg   P<.0005 +  424.mg 2.57gm   0/34    9/32
 nas car e      3.53gm   P<.05   +  1.07gm n.s.s.   0/35    3/37
 liv ang e      4.48gm   P<.09   +  1.10gm n.s.s.   0/32    2/31
 for ivc e      6.12gm   P<.2    +  996.mg n.s.s.   0/44    1/21
 liv hpt e      no dre   P=1.       523.mg n.s.s.   3/15    3/15
 tba mal e      131.mg   P<.0005    70.6mg 260.mg  11/45   36/39
 tba car        219.mg   P<.0005    134.mg 382.mg   1/50   30/40
628  R m sda inh 98w98 518                           0    50.4mg                                          Snyder;jtxe,4,605-618;1978
 liv tum        no dre   P=1.    -  415.mg n.s.s.   0/27    0/45
 tba tum        no dre   P=1.    -  415.mg n.s.s.   0/27    0/45
629  R m sda inh 29m29 2305                          0    16.7mg                                          Snyder;ajim,5,429-434;1984
 liv mix s      152.mg   P<.02      52.6mg n.s.s.   0/40    4/40
 zym car s      313.mg   P<.1       76.9mg n.s.s.   0/40    2/40
 --- grl s      634.mg   P<.3       103.mg n.s.s.   0/40    1/40
 mgl adc s      634.mg   P<.3       103.mg n.s.s.   0/40    1/40
 tba mix s      65.9mg   P<.02      27.7mg n.s.s.   3/40   11/40
 tba mal s      93.4mg   P<.04      35.5mg n.s.s.   2/40    8/40
 tba ben s      305.mg   P<.3       67.3mg n.s.s.   1/40    3/40
630  R f wis gav 24m24 BT907                         0    321.mg                                       Maltoni;anya,534,412-426;1988
 zym sqc        1.36gm   P<.004     552.mg 8.18gm   0/40    6/40
 orc sqc        2.09gm   P<.02      722.mg n.s.s.   0/40    4/40
 nas ulc        8.70gm   P<.3       1.42gm n.s.s.   0/40    1/40
 tba mal        482.mg   P<.02      217.mg n.s.s.  10/40   21/40
 tba mix        no dre   P=1.       408.mg n.s.s.  34/40   27/40
631  R m wis gav 24m24 BT907                         0    321.mg
 zym sqc        1.14gm   P<.002     494.mg 4.73gm   0/40    7/40
 nas ulc        4.29gm   P<.1       1.06gm n.s.s.   0/40    2/40
 orc sqc        8.48gm   P<.6       1.16gm n.s.s.   1/40    2/40
 tba mal        523.mg   P<.01      238.mg 26.9gm   8/40   19/40
 tba mix        no dre   P=1.       490.mg n.s.s.  30/40   23/40
Mutagenicity in Salmonella: negative
SMILES Code for Benzene: C1=CC=CC=C1
InChI Code for Benzene: InChI=1/C6H6/c1-2-4-6-5-3-1/h1-6H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Benzene: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007